Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Glycoprotein 41 (gp41) Overview | 8 | 1 |
| Therapeutics Development | 9 | 3 |
| Glycoprotein 41 (gp41) Products under Development by Stage of Development | 9 | 1 |
| Glycoprotein 41 (gp41) Products under Development by Therapy Area | 10 | 1 |
| Glycoprotein 41 (gp41) Products under Development by Indication | 11 | 1 |
| Glycoprotein 41 (gp41) Pipeline Products Glance | 12 | 2 |
| Late Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Glycoprotein 41 (gp41) Products under Development by Companies | 14 | 2 |
| Glycoprotein 41 (gp41) Products under Development by Universities/Institutes | 16 | 2 |
| Glycoprotein 41 (gp41) Therapeutics Assessment | 18 | 6 |
| Assessment by Monotherapy/Combination Products | 18 | 1 |
| Assessment by Mechanism of Action | 19 | 1 |
| Assessment by Route of Administration | 20 | 2 |
| Assessment by Molecule Type | 22 | 2 |
| Glycoprotein 41 (gp41) Companies Involved in Therapeutics Development | 24 | 10 |
| Amunix Operating Inc. | 24 | 1 |
| BioClonetics Immunotherapeutics, Inc. | 25 | 1 |
| Frontier Biotechnologies Co., Ltd | 26 | 1 |
| InnaVirVax SA | 27 | 1 |
| Laboratorios Del Dr. Esteve S.A. | 28 | 1 |
| Longevity Biotech, Inc | 29 | 1 |
| Mymetics Corporation | 30 | 1 |
| Navigen Pharmaceuticals, Inc. | 31 | 1 |
| Osel, Inc. | 32 | 1 |
| Pharis Biotec GmbH | 33 | 1 |
| Glycoprotein 41 (gp41) Drug Profiles | 34 | 29 |
| Biologic for Infectious Disease Drug Profile | 34 | 2 |
| CLONE-3 Drug Profile | 36 | 1 |
| CPT-31 Drug Profile | 37 | 1 |
| DS-007 Drug Profile | 38 | 1 |
| Enfuvirtide-XTEN Drug Profile | 39 | 2 |
| FB-006M Drug Profile | 41 | 2 |
| HIV vaccine Drug Profile | 43 | 2 |
| HIV-1 vaccine Drug Profile | 45 | 1 |
| LBT-5001 Drug Profile | 46 | 1 |
| Monoclonal Antibodies to Target GP120 and GP41 for HIV Drug Profile | 47 | 1 |
| MYMV-101 Drug Profile | 48 | 3 |
| MYMV-201 Drug Profile | 51 | 1 |
| Recombinant Peptides for HIV-1 Drug Profile | 52 | 1 |
| Sifuvirtide Drug Profile | 53 | 1 |
| Small Molecules to Target GP120 and Gp41 for HIV-1 Infections Drug Profile | 54 | 1 |
| STOP-3S Drug Profile | 55 | 1 |
| Synthetic Peptide to Target gp41 for HIV Infection Drug Profile | 56 | 1 |
| Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection Drug Profile | 57 | 1 |
| VAC-02 Drug Profile | 58 | 1 |
| VAC-3S Drug Profile | 59 | 2 |
| VIR-353 Drug Profile | 61 | 1 |
| VIR-576 Drug Profile | 62 | 1 |
| Glycoprotein 41 (gp41) Dormant Projects | 63 | 1 |
| Glycoprotein 41 (gp41) Featured News &Press Releases | 64 | 13 |
| Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial | 64 | 1 |
| Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic | 64 | 2 |
| Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine | 66 | 1 |
| Oct 28, 2014: Amunix and PolyPeptide Enter Into Partnership to Produce XTEN Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics | 67 | 1 |
| Jul 23, 2014: Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry" | 67 | 1 |
| Dec 01, 2013: InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used in Combination With Standard Antiretroviral Therapy in Treatment of HIV-Infection | 68 | 1 |
| Mar 05, 2013: InnaVirVax Presents Results From Phase I/IIa Clinical Study Of VAC-3S At CROI 2013 | 69 | 1 |
| Feb 21, 2013: Mymetics Announces Publication Of Positive Phase I Study Results Of HIV-1 Vaccine In PLOS ONE | 69 | 1 |
| Nov 30, 2012: InnaVirVax's HIV Vaccine VAC-3S Achieves Primary End Point In Phase I/IIa Study | 70 | 1 |
| Jun 18, 2012: InnaVirVax Files New European Patent Application For VAC-3S Immunotherapy | 71 | 1 |
| Mar 05, 2012: InnaVirVax Initiates Phase I/IIa Clinical Trial Of VAC-3S For Treatment Of HIV Infections | 71 | 1 |
| Oct 13, 2011: InnaVirVax Obtains Authorization From French Drug Agency To Start Phase I/IIa Study Of VAC-3S | 72 | 1 |
| Sep 19, 2011: HIVACAT identifies candidate to HIV vaccine and initiates animal experimentation | 73 | 1 |
| Jun 22, 2011: InnaVirVax Announces Positive Preclinical Results Of VAC-3S For Treatment Of HIV Infections | 74 | 1 |
| May 26, 2011: Mymetics Realizes Successful Phase I Study With New HIV Vaccine MYM-V101 | 75 | 2 |
| Appendix | 77 | 2 |
| Methodology | 77 | 1 |
| Coverage | 77 | 1 |
| Secondary Research | 77 | 1 |
| Primary Research | 77 | 1 |
| Expert Panel Validation | 77 | 1 |
| Contact Us | 77 | 1 |
| Disclaimer | 78 | 1 |